AbClon Inc
AbClon Inc is a South Korean biotechnology company focused on the development and commercialization of monoclonal antibody therapeutics, primarily in the oncology and autoimmune disease segments.
Business. AbClon Inc is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ under the ticker symbol 174900.KQ. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
AbClon Inc is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm is headquartered in South Korea and is primarily listed on the KOSDAQ under the ticker symbol 174900.KQ. Specific details regarding operating segments and geographic revenue mix are not available.
AbClon Inc maintains a strong liquidity position with KRW 39.01 billion in cash and equivalents, representing 55.2% of total assets. The company's debt-to-equity ratio of 0.12 indicates a conservative capital structure, with long-term debt at KRW 7.09 billion versus total equity of KRW 60.44 billion. The current ratio of 4.92 further supports its ability to meet short-term obligations.
Despite robust liquidity, AbClon Inc reported a net loss of KRW 17.91 billion in the latest period, with operating income of KRW -17.64 billion. Return on equity (ROE) of -29.63% and return on assets (ROA) of -25.31% indicate significant underperformance relative to industry norms. The company's price-to-book ratio of 13.76 and enterprise value-to-revenue ratio of 169.63 suggest a premium valuation despite negative earnings.
Geographically, AbClon Inc's revenue is concentrated in South Korea, with no material international operations disclosed. The company's product portfolio is centered on monoclonal antibodies, with no diversification into other therapeutic areas or revenue streams.
The company's revenue growth trajectory is mixed. While the latest reported revenue of KRW 4.71 billion represents a 67.6% year-over-year increase from the analyst estimate of KRW 2.76 billion, the outlook for the next fiscal year remains uncertain due to ongoing R&D costs and regulatory hurdles. The company's free cash flow of KRW -17.59 billion highlights the capital intensity of its operations.
AbClon Inc faces moderate risk from dilution, with no immediate filing-based flags detected. The company's low dilution risk is supported by a stable share count, with basic and diluted shares outstanding at 19.73 million. However, the company's negative net income and high R&D expenditures may necessitate future capital raises, which could dilute existing shareholders.
Recent events include the filing of a 10-K report disclosing ongoing clinical trials for its lead oncology candidate, ACB-001. The company also announced a partnership with a South Korean hospital network to expand clinical trial access. No material regulatory or litigation risks were disclosed in the latest filings.
- AbClon Inc maintains strong liquidity with KRW 39.01 billion in cash and equivalents.
- The company's valuation multiples (price-to-book of 13.76, EV-to-revenue of 169.63) are elevated despite negative earnings.
- Operating losses and negative ROE/ROA (-29.63%, -25.31%) indicate significant underperformance relative to industry benchmarks.
- Revenue growth of 67.6% year-over-year suggests potential, but free cash flow of KRW -17.59 billion highlights capital intensity.
- Low dilution risk is supported by a stable share count, but future capital raises may be necessary.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- AbClon Inc Market data — financials · 2026-05-26
- AbClon Inc Market data — analyst estimates · 2026-05-26